zenocutuzumab
Merus
['cross tumor']
in case you missed it, updated results from the enrgy study presented at #asco22! zeno orr of 34% (27/79) across tumor types &amp; 42% (8/19) in pdac. median dor of 9.1 mo and extremely well tolerated. zeno has the potential to become new soc for this unmet clinical need. 
Medical Oncologist, Early Drug Development and Gynecologic Malignancies, Memorial Sloan Kettering Cancer Center.